Hy2Care is a company dedicated to fighting Osteoarthritis. At the beginning of this century, the World Health Organization forecasted that, without treatment, osteoarthritis will be the fourth leading cause of disability by 2020. Today, there is still no adequate solution for more than 100 million patients.
It is Hy2Care’s ambition to shake the management of this disabling disease by introducing the first cure. Our solution is based on a novel technology platform consisting of injectable hydrogels. Our hydrogel’s first application usage will be focused on treatment of osteoarthritis, and in particular repair of focal cartilage defects in the knee.